Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis.
Xu S, Li G, Ye X, Chen D, Chen Z, Xu Z, Daniele M, Tambone S, Ceccacci A, Tomei L, Ye L, Yu Y, Solbach A, Farmer SM, Stimming EF, McAllister G, Marchionini DM, Zhang S. Xu S, et al. Among authors: tomei l. PLoS Genet. 2022 Jul 19;18(7):e1010302. doi: 10.1371/journal.pgen.1010302. eCollection 2022 Jul. PLoS Genet. 2022. PMID: 35853002 Free PMC article.
NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse model.
Moretti D, Tambone S, Cerretani M, Fezzardi P, Missineo A, Sherman LT, Munoz-Sajuan I, Harper S, Dominquez C, Pacifici R, Tomei L, Park L, Bresciani A. Moretti D, et al. Among authors: tomei l. Free Radic Biol Med. 2021 Jan;162:243-254. doi: 10.1016/j.freeradbiomed.2020.10.022. Epub 2020 Oct 21. Free Radic Biol Med. 2021. PMID: 33096251
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction.
Colarusso S, De Simone D, Frattarelli T, Andreini M, Cerretani M, Missineo A, Moretti D, Tambone S, Kempf G, Augustin M, Steinbacher S, Munoz-Sanjuan I, Park L, Summa V, Tomei L, Bresciani A, Dominguez C, Toledo-Sherman L, Bianchi E. Colarusso S, et al. Among authors: tomei l. Bioorg Med Chem. 2020 Nov 1;28(21):115738. doi: 10.1016/j.bmc.2020.115738. Epub 2020 Aug 30. Bioorg Med Chem. 2020. PMID: 33065433
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro.
Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA. Migliaccio G, et al. Among authors: tomei l. J Biol Chem. 2003 Dec 5;278(49):49164-70. doi: 10.1074/jbc.M305041200. Epub 2003 Sep 8. J Biol Chem. 2003. PMID: 12966103 Free article.
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De Francesco R, Migliaccio G. Tomei L, et al. J Virol. 2003 Dec;77(24):13225-31. doi: 10.1128/jvi.77.24.13225-13231.2003. J Virol. 2003. PMID: 14645579 Free PMC article.
High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.
Ullman C, Mathonet P, Oleksy A, Diamandakis A, Tomei L, Demartis A, Nardi C, Sambucini S, Missineo A, Alt K, Hagemeyer CE, Harris M, Hedt A, Weis R, Gehlsen KR. Ullman C, et al. Among authors: tomei l. PLoS One. 2015 Aug 27;10(8):e0135278. doi: 10.1371/journal.pone.0135278. eCollection 2015. PLoS One. 2015. PMID: 26313909 Free PMC article.
114 results